https://www.nasdaq.com/press-release/biocryst-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2022-01-04
https://www.nasdaq.com/press-release/biocryst-to-present-at-40th-annual-j.p.-morgan-healthcare-conference-2022-01-04
https://www.nasdaq.com/press-release/biocryst-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2021-12-03
https://www.nasdaq.com/press-release/biocryst-begins-patient-enrollment-in-redeem-2-pivotal-trial-evaluating-bcx9930-as
https://www.nasdaq.com/press-release/royalty-pharma-acquires-additional-royalty-interests-in-bcx9930-and-orladeyo-from
https://www.nasdaq.com/press-release/biocryst-adds-%24350-million-in-new-financing-with-royalty-pharma-and-omers-capital
https://www.nasdaq.com/press-release/biocryst-to-present-at-upcoming-investor-conferences-2021-11-12
https://www.nasdaq.com/press-release/biocryst-presents-new-data-showing-sustained-reduction-of-hae-attack-rates-and
https://www.nasdaq.com/press-release/biocryst-reports-third-quarter-2021-financial-results-and-upcoming-key-milestones
https://www.nasdaq.com/press-release/biocryst-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2021-11-02
https://www.nasdaq.com/press-release/biocryst-appoints-jinky-ang-rosselli-chief-data-and-insights-officer-2021-11-01
https://www.nasdaq.com/press-release/biocryst-to-present-new-orladeyor-berotralstat-data-at-annual-scientific-meeting-of
https://www.nasdaq.com/press-release/biocryst-to-report-third-quarter-2021-financial-results-on-november-3-2021-10-20
https://www.nasdaq.com/press-release/biocryst-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2021-10-04
https://www.nasdaq.com/press-release/biocryst-to-present-at-2021-cantor-virtual-healthcare-conference-2021-09-21
https://www.nasdaq.com/press-release/biocryst-appoints-dr.-amy-mckee-to-board-of-directors-2021-09-20
https://www.nasdaq.com/press-release/nice-recommends-biocrysts-orladeyor-berotralstat-the-first-oral-once-daily-therapy-to
https://www.nasdaq.com/press-release/biocryst-announces-approval-of-orladeyor-berotralstat-in-united-arab-emirates-2021-09
https://www.nasdaq.com/press-release/biocryst-to-present-at-upcoming-investor-conferences-2021-09-03
https://www.nasdaq.com/press-release/biocryst-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2021-09-02
https://www.nasdaq.com/press-release/u.s.-government-exercises-option-to-purchase-additional-rapivabr-peramivir-injection
https://www.nasdaq.com/press-release/biocryst-appoints-dr.-steven-galson-to-board-of-directors-2021-08-26
https://www.nasdaq.com/press-release/biocryst-announces-acceptance-of-regulatory-applications-for-orladeyor-berotralstat
https://www.nasdaq.com/press-release/biocryst-withdraws-public-offering-2021-08-10
https://www.nasdaq.com/press-release/biocryst-commences-public-offering-of-common-stock-and-pre-funded-warrants-2021-08-09
https://www.nasdaq.com/press-release/biocryst-reports-second-quarter-2021-financial-results-and-upcoming-key-milestones
https://www.nasdaq.com/press-release/biocryst-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2021-08-03
https://www.nasdaq.com/press-release/biocryst-appoints-vincent-milano-to-board-of-directors-2021-07-28
https://www.nasdaq.com/press-release/biocryst-to-report-second-quarter-2021-financial-results-on-august-5-2021-07-22
https://www.nasdaq.com/press-release/biocryst-announces-designs-for-redeem-1-and-redeem-2-pivotal-trials-with-bcx9930-as
https://www.nasdaq.com/press-release/biocryst-reports-96-week-data-from-apex-2-showing-orladeyorberotralstat-reduced-hae
https://www.nasdaq.com/press-release/orladeyotm-berotralstat-data-to-be-presented-at-european-academy-of-allergy-and
https://www.nasdaq.com/press-release/biocryst-announces-acceptance-and-accelerated-review-of-the-orladeyotm-berotralstat
https://www.nasdaq.com/press-release/biocryst-launches-orladeyotm-berotralstat-in-germany-2021-06-03
https://www.nasdaq.com/press-release/biocryst-to-present-at-upcoming-investor-conferences-2021-05-26
https://www.nasdaq.com/press-release/biocryst-receives-uk-approval-of-orladeyotm-berotralstat-first-oral-once-daily
https://www.nasdaq.com/press-release/biocryst-reports-first-quarter-2021-financial-results-and-upcoming-key-milestones
https://www.nasdaq.com/press-release/biocryst-to-present-at-upcoming-investor-conferences-2021-05-05
https://www.nasdaq.com/press-release/biocryst-receives-european-commission-approval-of-orladeyotm-berotralstat-first-oral
https://www.nasdaq.com/press-release/biocryst-to-report-first-quarter-2021-financial-results-on-may-6-2021-04-22
https://www.nasdaq.com/press-release/biocryst-announces-approval-of-japanese-nhi-price-listing-of-orladeyotm-berotralstat
https://www.nasdaq.com/press-release/biocryst-to-present-at-20th-annual-needham-virtual-healthcare-conference-2021-04-07
https://www.nasdaq.com/press-release/biocrysts-oral-factor-d-inhibitor-bcx9930-advancing-to-pivotal-trials-in-pnh
https://www.nasdaq.com/press-release/biocryst-appoints-helen-thackray-m.d.-as-chief-research-and-development-officer-2021
https://www.nasdaq.com/press-release/biocryst-to-host-virtual-rd-day-on-march-22-2021-2021-03-15
https://www.nasdaq.com/press-release/early-access-to-biocrysts-berotralstat-granted-for-hae-patients-in-france-2021-03-11
https://www.nasdaq.com/press-release/biocryst-submits-marketing-authorization-application-for-uk-approval-of-orladeyotm
https://www.nasdaq.com/press-release/biocryst-receives-positive-chmp-opinion-for-orladeyotm-berotralstat-an-oral-once
https://www.nasdaq.com/press-release/biocryst-reports-fourth-quarter-and-full-year-2020-financial-results-and-upcoming-key
https://www.nasdaq.com/press-release/biocryst-to-present-at-upcoming-investor-conferences-2021-02-18
https://www.nasdaq.com/press-release/biocryst-to-report-fourth-quarter-and-full-year-2020-financial-results-on-february-25
https://www.nasdaq.com/press-release/biocryst-to-present-data-at-2021-american-academy-of-allergy-asthma-immunology-annual
https://www.nasdaq.com/press-release/biocryst-announces-fda-approval-of-supplemental-new-drug-application-for-rapivabr
https://www.nasdaq.com/press-release/biocryst-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2021-02-02
https://www.nasdaq.com/press-release/biocryst-announces-approval-of-orladeyotm-berotralstat-in-japan-for-the-prophylactic
https://www.nasdaq.com/press-release/biocryst-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2021-01-07
https://www.nasdaq.com/press-release/biocryst-to-present-at-39th-annual-j.p.-morgan-healthcare-conference-2021-01-06
https://www.nasdaq.com/press-release/biocryst-provides-update-on-galidesivir-program-2020-12-22
https://www.nasdaq.com/press-release/biocryst-announces-positive-phase-1-results-with-bcx9250-an-oral-alk-2-inhibitor-for
https://www.nasdaq.com/press-release/biocryst-announces-u.s.-availability-of-orladeyotm-berotralstat-for-the-treatment-of
https://www.nasdaq.com/press-release/biocryst-to-present-at-jmp-securities-hematology-summit-2020-12-11
https://www.nasdaq.com/press-release/royalty-pharma-acquires-royalty-interest-in-orladeyo-and-bcx9930-from-biocryst
https://www.nasdaq.com/press-release/biocryst-announces-%24325-million-of-funding-from-royalty-pharma-and-athyrium-capital
https://www.nasdaq.com/press-release/biocrysts-oral-factor-d-inhibitor-bcx9930-shows-high-potency-and-specificity-for
https://www.nasdaq.com/press-release/biocryst-announces-fda-approval-of-orladeyotm-berotralstat-first-oral-once-daily
https://www.nasdaq.com/press-release/biocryst-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2020-12-01
https://www.nasdaq.com/press-release/allergy-publishes-results-from-biocrysts-apex-j-trial-of-oral-once-daily-berotralstat
https://www.nasdaq.com/press-release/biocryst-to-present-at-upcoming-virtual-investment-conferences-2020-11-20
https://www.nasdaq.com/press-release/biocryst-presents-data-showing-sustained-attack-rate-reductions-improved-patient
https://www.nasdaq.com/press-release/biocryst-presents-new-data-highlighting-burden-of-therapy-with-current-injectable
https://www.nasdaq.com/press-release/biocryst-to-present-data-at-the-2020-ash-annual-meeting-2020-11-12
https://www.nasdaq.com/press-release/biocryst-reports-third-quarter-2020-financial-results-and-upcoming-key-milestones
https://www.nasdaq.com/press-release/biocryst-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2020-11-02
https://www.nasdaq.com/press-release/mhra-grants-hae-patients-early-access-to-biocrysts-berotralstat-in-united-kingdom
https://www.nasdaq.com/press-release/biocryst-to-present-abstracts-at-annual-scientific-meeting-of-american-college-of-0
https://www.nasdaq.com/press-release/biocryst-to-report-third-quarter-2020-financial-results-on-november-5-2020-10-22
https://www.nasdaq.com/press-release/journal-of-allergy-and-clinical-immunology-publishes-results-from-biocrysts-apex-2
https://www.nasdaq.com/press-release/biocryst-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2020-10-05
https://www.nasdaq.com/press-release/biocrysts-oral-factor-d-inhibitor-bcx9930-shows-clinical-benefit-as-monotherapy
https://www.nasdaq.com/press-release/biocryst-to-present-at-22nd-annual-h.c.-wainwright-global-investment-conference-2020
https://www.nasdaq.com/press-release/biocryst-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2020-09-03
https://www.nasdaq.com/press-release/u.s.-government-exercises-option-to-purchase-additional-rapivabr-from-biocryst-for
https://www.nasdaq.com/press-release/niaid-awards-biocryst-new-%2444-million-contract-to-advance-development-of-galidesivir
https://www.nasdaq.com/press-release/fda-grants-orphan-drug-designation-for-bcx9930-in-pnh-2020-08-31
https://www.nasdaq.com/press-release/biocryst-reports-second-quarter-2020-financial-results-and-upcoming-key-milestones
https://www.nasdaq.com/press-release/biocryst-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2020-08-04
https://www.nasdaq.com/press-release/fda-grants-fast-track-designation-for-bcx9930-in-pnh-2020-08-03
https://www.nasdaq.com/press-release/biocryst-to-report-second-quarter-2020-financial-results-on-august-6-2020-07-23
https://www.nasdaq.com/press-release/biocryst-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2020-07-02
https://www.nasdaq.com/press-release/galidesivir-stops-zika-viral-replication-in-primate-model-2020-06-10
https://www.nasdaq.com/press-release/biocryst-announces-berotralstat-expanded-access-program-for-patients-with-hereditary
https://www.nasdaq.com/press-release/hereditary-angioedema-patients-report-breakthrough-attacks-on-current-injectable
https://www.nasdaq.com/press-release/long-term-48-week-data-show-treatment-with-berotralstat-provides-robust-and-durable
https://www.nasdaq.com/press-release/biocryst-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2020-06-02
https://www.nasdaq.com/press-release/biocryst-announces-full-exercise-of-underwriters-option-to-purchase-additional-0
https://www.nasdaq.com/press-release/biocryst-to-present-at-jefferies-virtual-healthcare-conference-2020-05-28
https://www.nasdaq.com/press-release/biocryst-prices-public-offering-of-common-stock-and-pre-funded-warrants-2020-05-27
https://www.nasdaq.com/press-release/biocryst-commences-public-offering-of-common-stock-and-pre-funded-warrants-2020-05-27
https://www.nasdaq.com/press-release/biocryst-to-present-new-berotralstat-data-at-european-academy-of-allergy-and-clinical
https://www.nasdaq.com/press-release/biocryst-celebrates-hae-patients-with-hae-global-walk-2020-05-15
https://www.nasdaq.com/press-release/biocryst-to-present-at-upcoming-investor-conferences-2020-05-07
https://www.nasdaq.com/press-release/biocryst-reports-first-quarter-2020-financial-results-and-upcoming-key-milestones
https://www.nasdaq.com/press-release/new-composition-of-matter-patent-allowance-extends-protection-for-berotralstat-in-u.s
https://www.nasdaq.com/press-release/biocryst-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2020-05-04
https://www.nasdaq.com/press-release/biocryst-to-report-first-quarter-2020-financial-results-on-may-6-2020-04-22
https://www.nasdaq.com/press-release/biocryst-begins-clinical-trial-with-galidesivir-for-treatment-of-patients-with-covid
https://www.nasdaq.com/press-release/biocryst-to-present-at-19th-annual-needham-healthcare-conference-2020-04-08
https://www.nasdaq.com/press-release/biocryst-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2020-04-03
https://www.nasdaq.com/press-release/biocryst-appoints-anthony-doyle-chief-financial-officer-2020-04-02
https://www.nasdaq.com/press-release/european-medicines-agency-validates-marketing-authorization-application-for-oral-once
https://www.nasdaq.com/press-release/berotralstat-bcx7353-significantly-reduced-use-of-acute-on-demand-medicine-in-hae
https://www.nasdaq.com/press-release/biocryst-reports-fourth-quarter-and-full-year-2019-financial-results-and-upcoming-key
https://www.nasdaq.com/press-release/biocryst-begins-proof-of-concept-trial-in-pnh-patients-with-oral-factor-d-inhibitor
https://www.nasdaq.com/press-release/biocryst-to-present-at-barclays-global-healthcare-conference-2020-03-03
https://www.nasdaq.com/press-release/biocryst-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2020-03-02
https://www.nasdaq.com/press-release/biocryst-to-present-new-data-at-american-academy-of-allergy-asthma-immunology-annual
https://www.nasdaq.com/press-release/biocryst-appoints-alan-g.-levin-to-board-of-directors-2020-02-25
https://www.nasdaq.com/press-release/biocryst-to-report-fourth-quarter-and-full-year-2019-financial-results-on-march-5
https://www.nasdaq.com/press-release/fda-accepts-biocrysts-nda-for-oral-once-daily-berotralstat-bcx7353-to-prevent-hae
https://www.nasdaq.com/press-release/biocryst-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2020-02-06
https://www.nasdaq.com/press-release/biocryst-submits-japanese-new-drug-application-for-oral-once-daily-berotralstat-2020
https://www.nasdaq.com/press-release/biocryst-strengthens-commercial-rare-disease-leadership-2020-01-15
https://www.nasdaq.com/press-release/biocryst-to-provide-berotralstat-and-bcx9930-program-updates-at-38th-annual-j.p.
https://www.nasdaq.com/press-release/biocryst-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2020-01-06
https://www.nasdaq.com/press-release/biocryst-to-present-at-38th-annual-j.p.-morgan-healthcare-conference-2020-01-03
https://www.nasdaq.com/press-release/biocryst-submits-new-drug-application-for-oral-once-daily-berotralstat-bcx7353-to
https://www.nasdaq.com/press-release/biocryst-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2019-12-04
https://www.nasdaq.com/press-release/biocryst-announces-full-exercise-of-underwriters-option-to-purchase-additional-shares
https://www.nasdaq.com/press-release/biocryst-to-present-at-upcoming-investor-conferences-2019-11-14
https://www.nasdaq.com/press-release/biocryst-prices-public-offering-of-common-stock-2019-11-13
https://www.nasdaq.com/press-release/biocryst-commences-public-offering-of-common-stock-2019-11-12
https://www.nasdaq.com/press-release/biocryst-to-present-abstracts-at-annual-scientific-meeting-of-american-college-of
https://www.nasdaq.com/press-release/biocryst-reports-third-quarter-2019-financial-results-and-upcoming-key-milestones
https://www.nasdaq.com/press-release/new-clinical-trial-results-and-market-research-support-significant-commercial
https://www.nasdaq.com/press-release/biocryst-announces-partnership-with-torii-pharmaceutical-to-commercialize-bcx7353-in
https://www.nasdaq.com/press-release/biocryst-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2019-11-04
https://www.nasdaq.com/press-release/biocryst-begins-phase-1-trial-with-bcx9250-an-oral-alk-2-inhibitor-for-treatment-of
https://www.nasdaq.com/press-release/biocryst-to-provide-commercial-update-and-report-third-quarter-2019-financial-results
https://www.nasdaq.com/press-release/biocryst-reports-data-from-phase-1-trial-of-bcx9930-and-announces-plans-to-advance
https://www.nasdaq.com/press-release/biocryst-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2019-10-03
https://www.nasdaq.com/press-release/u.s.-government-exercises-option-for-additonal-rapivabr-for-strategic-national
https://www.nasdaq.com/press-release/biocryst-pharmaceuticals-to-present-at-cantor-global-healthcare-conference-2019-09-24
https://www.nasdaq.com/press-release/biocryst-appoints-helen-thackray-m.d.-to-board-of-directors-2019-09-23
https://www.nasdaq.com/press-release/biocryst-reports-fourth-quarter-and-full-year-2018-financial-results-2019-04-11
